Newsroom
Sorted by: Latest
-
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- ISIN Code. XS3085084559 Our Ref. MT3203 ISSUE NAME. ASB BANK LIMITED Issue of EUR 89,000,000.00 Floating Rate Senior Notes due 15 June 2026 series EMTN 6674 Tranche 1 MTN INTEREST PERIOD. 15/09/2025 TO 15/12/2025 VALUE DATE. 15/12/2025 INTEREST RATE. 2.32149 PCT NUM OF DAYS. 91 DAY BASIS. Actual/360 (A004) CURRENCY CODE. EUR TOTAL INTEREST AMT. EUR 522,270.76 POOL FACTOR. N/A...
-
Peer Software Recognized in the 2025 Gartner® Voice of the Customer for Hybrid Cloud Storage
CENTREVILLE, Va.--(BUSINESS WIRE)--Peer Software Recognized in the 2025 Gartner® Voice of the Customer for Hybrid Cloud Storage...
-
Causely Recognized as a Gartner® Cool Vendor for AI in IT Operations
NEW YORK--(BUSINESS WIRE)--Causely announces it has been named a Gartner Cool Vendor for AI in IT Operations....
-
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- ISIN Code. XS3084328239 Our Ref. MT3054 ISSUE NAME. ASB BANK LIMITED Issue of USD 100,000,000.00 Floating Rate Senior Notes due 15 June 2026 Series EMTN 6673 Tranche 1 MTN INTEREST PERIOD. 15/09/2025 TO 15/12/2025 VALUE DATE. 15/12/2025 INTEREST RATE. 4.60172 PCT NUM OF DAYS. 91 DAY BASIS. Actual/360 (A004) CURRENCY CODE. USD TOTAL INTEREST AMT. USD 1,163,212.56 POOL FACTOR. N/A...
-
Helium Network Expands to Brazil Through Partnership with Mambo WiFi, Launches International Waitlist
SAN FRANCISCO--(BUSINESS WIRE)--Helium, the leader in decentralized wireless communications today, is announcing a new joint venture with leading Brazilian WiFi company Mambo WiFi, to bring its people-powered wireless network to millions of mobile users in Brazil, marking a major step in Helium’s global expansion. The announcement was made at Solana Breakpoint, where Helium also unveiled an International Waitlist for communities and organizations interested in bringing the Helium Network to the...
-
Bespoke Partners’ AI Platform Slashes Executive Search Time by 30%, Redefining Leadership Acquisition for Private Equity
SAN DIEGO--(BUSINESS WIRE)--Bespoke Partners, the leading executive search firm for private equity portfolio companies, today announced groundbreaking results from its AI-powered Executive Index, transforming how private equity firms identify and hire portfolio company leaders by slashing search time-to-placement by 30%. Bespoke’s Executive Index is a proprietary AI-powered talent market mapping platform that is transforming executive recruiting for software and SaaS companies. The Index accele...
-
Heritage Insurance Company Deploys Guidewire to Modernize Policy Administration, Underwriting, and Billing Operations
TAMPA, Fla. & SAN MATEO, Calif.--(BUSINESS WIRE)--Heritage Insurance Company and Guidewire announced that Heritage successfully deployed Guidewire PolicyCenter and Guidewire BillingCenter....
-
Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- ISIN Code. XS2959610580 Our Ref. MS1410 ISSUE NAME. Commonwealth Bank of Australia Issue of EUR 400,000,000.00 Floating Rate Notes due December 2025 Series no 6652 Tranche 1 MTN INTEREST PERIOD. 12/09/2025 TO 12/12/2025 VALUE DATE. 12/12/2025 INTEREST RATE. 2.2013 PCT NUM OF DAYS. 91 DAY BASIS. Actual/360 (A004) CURRENCY CODE. EUR TOTAL INTEREST AMT. EUR 2,225,758.89 POOL FACTOR. N/A...
-
Arrowstreet Capital Ltd UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Arrowstreet Capital, Limited Partnership (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
EpilepsyGTx Raises $33 Million Series A to Develop Single Dose Gene Therapy for Focal Refractory Epilepsy
LONDON--(BUSINESS WIRE)--EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company. The funding will enable the delivery of first-in-human Phase 1/2a clinical trials to...